Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival
Omer Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, Kristen McCullough, Aref Al‐Kali, Hassan B. Alkhateeb, Kebede H. Begna, Michelle A. Elliott, Abhishek A. Mangaonkar, Antoine N. Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun Vinod Shah, Mrinal M. Patnaik, Animesh Pardanani, Talha Badar, Hemant S. Murthy, James M. Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y. Arana Yi, Ayalew Tefferi, Naseema Gangat
Abstract
Overall survival and response rates of 270 patients with newly diagnosed acute myeloid leukemia receiving venetoclax (Ven) plus hypomethylating agent, stratified by Ven dosing schedule (Cycle 1 Ven 14 vs. 21 vs. 28 days).
Topics & Concepts
VenetoclaxMedicineMyeloid leukemiaHypomethylating agentInternal medicineOncologyToxicityLeukemiaMyeloidBiologyGeneGeneticsChronic lymphocytic leukemiaDNA methylationGene expressionAcute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and TreatmentHistone Deacetylase Inhibitors Research